AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Vaxart Extends Cash Runway into Q2 2027 with Dynavax Partnership, Aims for 2026 Data Readouts
ByAinvest
Thursday, Nov 13, 2025 10:46 pm ET1min read
Vaxart has extended its cash runway into Q2 2027 through a partnership with Dynavax, which could bring up to $700 million in fees and royalties. The deal also includes milestone payments and regulatory fees. The company is targeting 2026 data readouts for its oral COVID-19 vaccine candidate.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet